Prolonged Enoxaparin In Primary Percutaneous Coronary Intervention; A Pilot Pharmacodynamic Study

Launched by SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST · May 9, 2017

Keywords

ClinConnect Summary

This is a single centre, pharmacodynamic pilot study of a prolonged enoxaparin infusion following the guideline directed bolus treatment in patients undergoing PPCI conducted at Sheffield Teaching Hospitals NHS Foundation Trust.

Patients admitted to the catheter laboratory or coronary care unit with STEMI and accepted for PPCI will be screened. Those meeting the inclusion criteria will be recruited following angiography. Aspirin is usually administered in the ambulance prior to patient's arrival to hospital and ticagrelor or prasugrel is given as soon as possible on arrival to hospital. Th...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18
• • Confirmation of the diagnosis of STEMI by the clinical team on the basis of history, ECG changes and angiographic findings
• • Pre-treatment with either ticagrelor or prasugrel
• • Intention to proceed with PPCI
• • Feasibility to obtain informed verbal consent pre PPCI
• Exclusion Criteria:
• • Active bleeding that cannot be controlled by local measures
• • Female patients of child bearing age who have not had a sterilisation procedure
• • Patients with end stage renal failure requiring renal replacement therapy
• • Known thrombocytopenia (Platelet count \< 100,000/μL)
• • Known history of intracranial haemorrhage
• • Known current treatment with oral anticoagulants
• • Known history of major surgery or trauma or history of GI/GU haemorrhage within the last month
• • Known intracranial malignancy or aneurysm
• • Known allergy to enoxaparin
• • Inability to easily understand verbal information given in English for any reason
• • Inability to give informed consent due to either temporary or permanent mental incapacity